A Study of ZW191 in Participants With Solid Tumors
- Trial number:
- NCT06555744
- Trial phase:
- 1
- Study type:
- Targeted therapy
- Overall status:
- Recruiting
Study start date
October, 2024
Scientific title
A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors
Summary
The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.
* Pathologically or cytologically confirmed diagnosis of cancers with evidence of locally advanced (unresectable), recurrent and/or metastatic disease.* Measurable disease per RECIST v1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. * Adequate cardiac function: Cardiac left ventricular function, as defined by left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram (ECHO) or multigated acquisition scan (MUGA). * Other adequate organ function.
Study design
Primary purpose:
TREATMENT, Allocation:
NA, Intervention model:
SINGLE_GROUP, Masking:
NONE,
Conditions
Advanced Solid Tumors
Other study ID numbers
2024-512299-37-00; ZWI-ZW191-101